MX2015009155A - Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. - Google Patents

Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.

Info

Publication number
MX2015009155A
MX2015009155A MX2015009155A MX2015009155A MX2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A
Authority
MX
Mexico
Prior art keywords
alpha
receptor agonists
acetylcholine receptor
nicotinic acetylcholine
recovery
Prior art date
Application number
MX2015009155A
Other languages
English (en)
Other versions
MX378251B (es
Inventor
Dominik Feuerbach
Markus Fendt
Cristina Lopez-Lopez
Kevin Hall Mcallister
Judit Sovago
Markus Weiss
Donald Johns
Christer Halldin
Johannes Sjoerd Finnema
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015009155A publication Critical patent/MX2015009155A/es
Publication of MX378251B publication Critical patent/MX378251B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Emergency Medicine (AREA)

Abstract

La invención se refiere al uso de cierto agonista del receptor nicotínico de acetilcolina alfa 7 para facilitar la recuperación de la anestesia general.
MX2015009155A 2013-01-15 2014-01-13 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. MX378251B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361752772P 2013-01-15 2013-01-15
PCT/IB2014/058225 WO2014111838A1 (en) 2013-01-15 2014-01-13 Use of alpha 7 nicotinic acetylcholine receptor agonists

Publications (2)

Publication Number Publication Date
MX2015009155A true MX2015009155A (es) 2016-03-04
MX378251B MX378251B (es) 2025-03-10

Family

ID=50070639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009155A MX378251B (es) 2013-01-15 2014-01-13 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.

Country Status (10)

Country Link
EP (1) EP2945633B1 (es)
JP (1) JP6338223B2 (es)
KR (1) KR101879920B1 (es)
CN (1) CN105263495B (es)
BR (1) BR112015016995B8 (es)
CA (1) CA2898080C (es)
ES (1) ES2883232T3 (es)
MX (1) MX378251B (es)
TW (1) TWI633886B (es)
WO (1) WO2014111838A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020105929A (ru) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. Способы и композиции для модулирования сплайсинга
WO2019100155A1 (en) * 2017-11-22 2019-05-31 The Governors Of The University Of Alberta Method of countering respiratory depression via activation of neuronal heteromeric nicotinic acetylcholine receptors
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
EP3920926A4 (en) 2019-02-05 2022-10-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP7801365B2 (ja) * 2021-04-02 2026-01-16 ウェストチャイナホスピタル、スーチョワンユニバーシティ 環状ケトン系化合物の新たな使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
CA2551486A1 (en) 2003-12-22 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US7872017B2 (en) 2006-05-19 2011-01-18 Abbott Laboratories Fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN100448468C (zh) * 2006-11-14 2009-01-07 赵玉民 一种口服用于治疗胃病的药粉
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
BRPI0920187A2 (pt) 2008-10-13 2019-08-27 Hoffmann La Roche método sem diazônio para fabricar um indazol intermediário na síntese de amidas bicíclicas do ácido 5-(triflúor-metóxi)-1h-3-indazol-carboxílico
US20110262407A1 (en) 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
ES2539464T3 (es) * 2010-11-10 2015-07-01 H. Lundbeck A/S Ligandos basados en el fenilimidazol radiomarcados
MX2013008704A (es) * 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
CN103619354A (zh) * 2011-06-30 2014-03-05 东丽株式会社 止痒剂

Also Published As

Publication number Publication date
JP6338223B2 (ja) 2018-06-06
ES2883232T3 (es) 2021-12-07
EP2945633B1 (en) 2021-06-30
CA2898080C (en) 2018-01-09
KR101879920B1 (ko) 2018-07-18
CA2898080A1 (en) 2014-07-24
EP2945633A1 (en) 2015-11-25
BR112015016995A2 (pt) 2017-07-11
TWI633886B (zh) 2018-09-01
CN105263495B (zh) 2019-05-14
CN105263495A (zh) 2016-01-20
WO2014111838A1 (en) 2014-07-24
TW201440766A (zh) 2014-11-01
BR112015016995A8 (pt) 2018-01-23
KR20150105469A (ko) 2015-09-16
MX378251B (es) 2025-03-10
BR112015016995B8 (pt) 2022-07-26
BR112015016995B1 (pt) 2022-02-01
JP2016509595A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
UY4211Q (es) Pizarra para marcadores
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
PL3587417T3 (pl) Benzamidy podstawione 1,3-tiazol-2-ilem
GEAP201914307A (en) 4'-substituted nucleosidederivatives as hiv reverse transcriptase inhibitors
MX2015009155A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
BR112017006232A2 (pt) processos e intermediários na preparação de antagonistas de c5ar
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
GEAP201814347A (en) Substituted dihydroisoquinoline compounds
PL3071593T3 (pl) Konstruowane ludzkie receptory komórek T o wysokim powinowactwie
SG10201811017QA (en) Novel antibody frameworks
IL245471B (en) Fluorinated compounds as alpha v integrin receptor antagonists
CO2017004532A2 (es) Síntesis de copanlisib y su sal diclorhidrato
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
PT3192922T (pt) Óleo para fibra acrílica precursora de fibra de carbono, composição de óleo para fibra acrílica precursora de fibra de carbono, líquido de tratamento de óleo para fibra acrílica precursora de fibra de carbono e feixe de fibras acrílicas precursoras de fibras de carbono
CL2015002358A1 (es) Compuestos bicíclicos.
CR20160187A (es) Anticuerpos anti-ccl 17
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
UA116372C2 (uk) Частинки резинату фенілефрину
MX384260B (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
ES1105380Y (es) Estructura lineal empotrable para iluminacion.
BR112016028941A2 (pt) uso de antiespumantes como aditivos antideriva".
TWD158113S (zh) 窗簾下軌